Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. [electronic resource]
Producer: 20200921Description: 57-60 p. digitalISSN:- 2210-7762
- Adult
- Aged
- Aged, 80 and over
- Anaplastic Lymphoma Kinase -- analysis
- Carbazoles -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Clinical Decision-Making -- methods
- Crizotinib -- pharmacology
- False Positive Reactions
- Female
- Follow-Up Studies
- Gene Rearrangement
- Humans
- In Situ Hybridization, Fluorescence -- statistics & numerical data
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Piperidines -- pharmacology
- Progression-Free Survival
- Proportional Hazards Models
- Protein Kinase Inhibitors -- pharmacology
- Retrospective Studies
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.